Serum Triglyceride Levels In Patients Research Articles

Correlations between Gut Microbiota and Hematological, Inflammatory, Biochemical and Oxidative Stress Parameters in Treatment-Naïve Psoriasis Patients.

Psoriasis is an inflammatory dermatosis with a complex pathogenesis, significantly impacting the quality of life of patients. The role of oxidative stress and gut microbiota in the pathogenesis of this disease is increasingly studied, appearing to underlie the comorbidities associated with this condition. We present the first prospective observational study conducted in Romania evaluating the interrelationship between gut microbiota and hematological, inflammatory, biochemical, and oxidative stress parameters in treatment-naïve psoriasis patients. Significant differences were observed in terms of microbiota composition, with lower levels of Firmicutes and Enterobacteriaceae in the psoriasis group compared to the control group. Moreover, a negative correlation was found between the serum triglyceride levels in patients with psoriasis and the Enterobacteriaceae family (p = 0.018, r = -0.722), and a positive correlation was found between the serum glucose levels and the Firmicutes/Bacteroides ratio (p = 0.03, r = 0.682). Regarding the oxidant-antioxidant status, a significant correlation was found between the FORT level and Lactobacillus (p = 0.034, r = 0.669). Lastly, the Firmicutes level negatively correlated with the DLQI level, independent of the clinical severity of the disease (p = 0.02, r = -0.685). In conclusion, even though the number of included patients is small, these results may serve as a starting point for future research into the involvement of the microbiota-inflammation-oxidative stress axis in psoriasis development.

A STUDY OF LIPID PROFILE IN ANAEMIA

Objectives:Both anemia and dyslipidemia are widely prevalent public health problems, especiallyin the Indian population. Associationof anemia and dyslipidemias were reported in some individual experimental animals. The study was planned to find thechanges in serum lipid profile in adult Indian patients with anemia. Material and methods:100 cases of anemia (hemoglobin <13 g% in men and <12 g% in women), and 100 age and sex matched healthy controls, in the age group 18-40 years were investigated for any possible changes in serum lipid profile i.e.,triglycerides, total cholesterol, high density lipoprotein cholesterol, very low density lipoprotein cholesterol. Results:The mean cholesterol in patients with anemia was 122.47 ± 29.32 mg/dl, whereas in controls group was 160.43 ± 38.91 mg/dl. The mean serum triglyceride level in patients with anemia was 89.41 ± 33.1532 mg/dl and in control group was 111.45 ± 40.6632 mg/dl. Mean high-density lipoprotein levels were 36.13 ± 12.8132 mg/dl in anemic group and 45 ± 13.032 mg/dl in control group, whereas low-density lipoprotein (LDL) cholesterol level was 70.12 ± 21.64 mg/dl in the anemic group and 100.45 ± 30.8032 mg/dl in control group. VLDL levels were higher in control group (21.96 ± 8.132 mg/dl) compared to the anemic group (18.34 ± 7.6432 mg/dl). Conclusion: Lipoproteins levels were significantly abnormal in anemic as compared to non-anemic subjects.

Intestinal Absorption of Lipids Using a Pancreatic Enzyme-Free Nutritional Supplement in Patients with Cystic Fibrosis: A Randomized, Double-Blind, Crossover Pilot Trial.

Nutritional supplements for patients with exocrine pancreatic insufficiency (EPI) typically utilize pancreatic enzyme replacement therapy (PERT) which is associated with gastrointestinal side effects. We evaluated serum triglyceride levels in patients with cystic fibrosis following consumption of an enzyme-modified oil oral nutritional supplement (EMO-ONS) versus a standard triacylglycerol-based ONS product (TAG-ONS) used concomitantly with PERT and patient tolerability between the two approaches. Ten subjects with CF and EPI taking PERT were enrolled in a single-center, double-blind, cross-over proof of concept trial. Five subjects randomized to Arm 1 were administered a PERT placebo and EMO-ONS and 5 subjects in Arm 2 were administered TAG-ONS+PERT. After 4 to 14 days, subjects received the opposite ONS. Serum triglyceride levels were measured at baseline and hourly for 6 h. Following the above, subjects were randomly assigned to receive 2 daily servings of EMO-ONS+PERT placebo or TAG-ONS+PERT at home for 7-days, self-reporting gastrointestinal symptoms daily. Mean change in peak serum triglyceride levels were similar for both groups (EMO-ONS = 41.9 ± 46.7 mg/dL vs. TAG-ONS+PERT = 46.4 ± 44.1 mg/L; p = 0.85). There was no difference in mean ratio of the serum triglyceride AUC between the two groups (p = 0.58) or self-reported gastrointestinal tolerance. EMO-based products may provide a PERT-free alternative to traditional ONS products in patients with cystic fibrosis.

The Effect of Admission Serum Triglyceride Level on the Prediction of Severity of Acute Pancreatitis in Pregnancy.

PurposePrevious studies indicated that the serum triglyceride level in patients with acute pancreatitis positively correlated with the severity of the disease among the general population. Despite the physiological hypertriglyceridemia in pregnant women, there are no reports on the relationship between serum triglyceride level and the severity of acute pancreatitis in pregnant (APIP) women. This study explores the relationship between serum triglyceride levels and the severity of APIP.Patients and MethodsClinical information of APIP patients admitted to the Shengjing Affiliated Hospital of China Medical University was gathered from January 2012 to December 2020 to conduct retrospective research. The participating patients were divided into mild, moderately severe, and severe acute pancreatitis. The clinical outcomes of patients with different serum triglyceride levels (0–2.3 mmol/L, 2.23–5.65 mmol/L, 5.65–11.2 mmol/l, ≥11.2 mmol/L) were analyzed by performing ordinal logistic regression analysis. Receiver operating curve analysis was used to calculate the threshold value of serum triglyceride concentration that can effectively predict the occurrence of severe acute pancreatitis (SAP).ResultsHypertriglyceridemic acute pancreatitis (HTG-AP) occurred in 47% of APIP patients within the group, with a high prevalence among the Han population. In the present study, the serum triglyceride concentration correlated positively with the severity of APIP (r=0.403, P < 0.05). The adjusted logistic model demonstrated that relative to nominal triglyceride levels, the OR value of SAP were 1.036 (95% CI: 0.401–2.677), 3.429 (95% CI: 1.269–9265), 8.329 (95% CI: 3.713–18.682) with triglyceride at the level of 2.23–5.65 mmol/L, 5.65–11.2 mmol/l and ≥11.2 mmol/L. In APIP patients, a triglyceride concentration of 10.7mmol/L or more upon admission was a predictive value for the occurrence of SAP, with a sensitivity of 0.72 and a specificity of 0.65, AUC: 0.708 (95% CI: 0.620–0.796).ConclusionAs the serum triglyceride level upon admission increased, the frequency of local and systemic complications increased significantly.

Comparison of Serum Triglyceride and Cholesterol Levels in Premature Neonates with or without Respiratory Distress Syndrome (RDS).

Background Deficiency or reduced transmission of long-chain fatty acids and essential fatty acids may inhibit lung growth and development. We aimed to evaluate and compare serum triglyceride and cholesterol levels in premature neonates with RDS. Methods This study is a cross-sectional study performed on premature neonates born in Beheshti Hospital in Isfahan in 2018. Immediately after birth and after umbilical cord clumping, blood samples were taken from the umbilical artery and triglyceride and total cholesterol levels were measured. Those patients with the diagnosis of RDS were transferred to the neonatal intensive care unit (NICU). Data regarding the laboratory results of the lipid profile in patients were compared to that in the other group. Results A total number of 100 neonates entered the study and were divided into 2 groups. Analysis of gender and mean gestational ages among the two groups showed no significant differences between the groups (P = 0.84 and P = 0.28, respectively). Further analysis showed a significant decreased serum cholesterol in the group 1 of patients (P = 0.01), but there were no significant differences between the two groups regarding triglyceride levels (P = 0.43). There was a significant direct relationship between gestational age and serum triglyceride levels in patients with RDS (r = 0.550, P < 0.001). Conclusion Here, we indicated significantly lower cholesterol levels in the cord serum of premature neonates with RDS compared to non-RDS premature neonates. Our data also showed a significant direct relationship between gestational age and serum triglyceride levels in patients with RDS. These data were in line with the previous studies.

GCSF deficiency attenuates nonalcoholic fatty liver disease through regulating GCSFR-SOCS3-JAK-STAT3 pathway and immune cells infiltration.

Granulocyte colony stimulating factor (GCSF) is a cytokine with immunomodulation effects. However, little is known about its role in metabolic diseases. In the current study, we aimed to explore the role of GCSF in nonalcoholic fatty liver disease (NAFLD). Male GCSF-/- mice were used to investigate the function of GCSF in vivo after high-fat diet (HFD). Primary hepatocytes were used for evaluating the function of GCSF in vitro. Liver immune cells were isolated and analyzed by flow cytometry. Our results showed that GCSF administration significantly increased serum triglyceride (TG) levels in patients. Circulating GCSF was markedly elevated in HFD-fed mice. GCSF-/- mice exhibited alleviated HFD-induced obesity, insulin resistance, and hepatic steatosis. Extra administration of GCSF significantly aggravated palmitic acid (PA)-induced lipid accumulation in primary hepatocytes. Mechanically, GCSF could bind to granulocyte colony stimulating factor receptor (GCSFR) and regulate suppressors of cytokine signaling 3, Janus kinase, signal transducer and activator of transcription 3 (SOCS3-JAK-STAT3) pathway. GCSF also enhanced hepatic neutrophils and macrophages infiltration, thereby modulating NAFLD. These findings suggest that GCSF plays an important regulatory role in NAFLD and may be a potential therapeutic target for NAFLD.NEW & NOTEWORTHY We found GCSF was involved in lipid metabolism and NAFLD development. GCSF administration increased serum triglyceride levels in patients. GCSF deficiency alleviated HFD-induced insulin resistance and hepatic steatosis in mice. GCSF could directly act on hepatocytes through GCSFR-SOCS3-JAK-STAT3 pathway, and regulate the infiltration of immune cells into the liver to indirectly modulate NAFLD. Our finding indicates that GCSF may provide new strategies for the treatment of NAFLD.

Association Study between Serum Triglyceride Level and Glucose and Lipid Metabolism in Patients with Polycystic Ovary Syndrome

To investigate the serum triglyceride levels and their correlation with glycolipid metabolism in patients with polycystic ovary syndrome. 108 patients who were diagnosed with polycystic ovary syndrome for the first time at the Department of Obstetrics and Gynecology of our hospital from May 2018 to June 2019 were collected. They were divided into an obesity group (n=64) and a non-obesity group (n=36) according to body mass index and a control group of 36 healthy medical examiners with body mass index similar to those of the patients during the same period was selected. The glucose and lipid metabolism levels of the participants were measured by oral glucose tolerance test and insulin release test. Serum triglyceride levels were significantly higher in the obesity and non-obesity groups than in the control group (p<0.05). The serum triglyceride levels in the obesity and non-obesity groups were significantly higher than those in the control group (p<0.05) and the obesity group had the highest triglyceride content. The glucose metabolism level in the non-obesity group was significantly higher than that in the control group (p<0.05). The Homeostatic model assessment-beta in the control group was significantly higher than that in the obesity group and the non-obesity group, the obesity group had the lowest Homeostatic model assessment-insulin resistance; the Homeostatic model assessment-insulin resistance in the control group was significantly lower than that in the other two groups and the obesity group had the lowest Homeostatic model assessment-insulin resistance (p<0.05). Serum triglyceride levels in patients with polycystic ovary syndrome can reflect changes in glucose and lipid metabolism and triglyceride as an inexpensive and routine test can be considered as a surrogate indicator of insulin resistance in non-obesity patients with polycystic ovary syndrome.

ASSOCIATION BETWEEN TRIGLYCERIDE SERUM LEVELS AND GLOMERULAR FILTRATION RATE (eGFR) IN PATIENTS WITH CHRONIC RENAL FAILURE AT JEMURSARI ISLAMIC HOSPITAL SURABAYA, INDONESIA

Chronic Renal Failure (CRF) is a progressive and irreversible decrease in kidney function. One risk factor that affects the progression of CRF is dyslipidemia due to abnormalities of lipid metabolisms. Dyslipidemia is characterized by the increase level of total cholesterol, LDL cholesterol, triglycerides, and a decrease in HDL cholesterol level. eGFR is a parameter for assessing the excretion function, by calculating the amount of filtrate produced by the renal glomerulus. This study aims to determine the relationship between serum triglyceride levels with eGFR in patient suffering from CRF at Jemursari Islamic Hospital Surabaya. This type of research is descriptive experimental with cross–sectional design. The study population was the patients with CRF. The primary data in this study was the results of examination of serum triglyceride levels in patients with CRF. The secondary data (serum creatinine levels, body weight, age, and sex) was obtained from medical records of CRF patients in February 2019. As much as 12% of patients were in the 40–50 years old category, 36% of patients were 51–60 years old, 44% of patients were 61–70 years old, and 8% of patients were 71–80 years old. 72% of patients were male. The mean triglyceride level was 146.68 mg/dL and the average eGFR was 19.86 mL/min/1.73m2. The relationships between triglyceride levels and eGFR was carried out by the Spearman–rho test where r value was –0.442 and value was 0.027. It was concluded that there was a significant negative correlation between serum triglyceride levels and eGFR in patients with CRF.

Psöriyazisli Hastalarda Serum Midkin Seviyeleri

Objectives: Midkine is a heparin-binding growth factor which functions in development and repair mechanisms. It also has roles in tumor growth, invasion and angiogenesis in cancer cells. Recently, higher serum midkine levels were detected in inflammatory diseases such as rheumatoid arthritis, inflammatory bowel diseases, atherosclerosis and obesity. In the present study, we aimed to investigate serum midkine levels in patients with psoriasis. We also tried to reveal if there is a relationship between serum midkine levels and psoriasis disease activity. Material and Methods: Forty-five patients with psoriasis and age, sex-matched healthy controls were enrolled in the study. Serum midkine level, complete blood count, fasting serum glucose level, lipid profile (HDL, LDL, triglyceride, cholesterol), CRP (C-reactive protein), serum liver function tests (ALT; AST) and kidney function tests (urea and creatinine) were studied. Psoriasis area severity index (PASI) scores and body mass indexes were calculated for each patient. Results: We found significantly higher serum midkine levels in patients with psoriasis compared to control group. There was no correlation between serum midkine levels and PASI scores. Serum midkine levels were correlated with serum triglyceride levels in patients with psoriasis. Conclusion: This study showed that serum midkine levels were significantly higher in psoriatic patients than controls. As midkine is only correlated with serum triglyceride level and not correlated with PASI, we think serum midkine is not an ideal serum marker for the evaluation of psoriasis activity.

Orlistat therapy for children with type 1 hyperlipoproteinemia: a randomized clinical trial

Context Patients with type 1 hyperlipoproteinemia (T1HLP), a rare genetic disorder, have extreme chylomicronemia and recurrent episodes of acute pancreatitis. Currently, the only therapeutic option is to consume an extremely low-fat diet because the triglyceride-lowering medications are not efficacious. Objective To determine the efficacy of orlistat, a gastric and pancreatic lipase inhibitor, in reducing serum triglyceride levels in patients with T1HLP. Design and setting We conducted a randomized, open-label, clinical trial with a four-period, two-sequence (orlistat and for 3 months), crossover study design. Patients Two unrelated young Asian Indian males (11 and 9 years old) with T1HLP due to homozygous large GPIHBP1 deletions were enrolled at the UT Southwestern Medical Center. The patients were randomized to receive 3 months of orlistat or no therapy (off), then crossed over to the other arm, and this sequence was then repeated. Fasting serum triglyceride levels, fat-soluble vitamins, and gastrointestinal side effects were assessed. Results Compared with the two off periods, orlistat therapy reduced serum triglycerides by 53.3% and 53.0% in patient 1 and 45.8% and 62.2% in patient 2. There was no deficiency of fat-soluble vitamin levels, and their growth continued. There were no serious adverse effects of orlistat; patient 1 had a mild increase in passage of gas and bloating, and patient 2 had constipation with mild stool leakage. Conclusion Orlistat is safe and highly efficacious in lowering serum triglycerides in children with T1HLP and should be the first-line therapy in conjunction with an extremely low-fat diet.

The effect of omega-3 supplementation on glycemic indices and lipid profile in type 2 diabetic patients with non-alcoholic fatty liver disease: A double-blind, randomized, clinical trial

INTRODUCTION: Serum phospholipid omega-3 fatty acid levels in patients suffering from both type 2 diabetes (T2DM) and non-alcoholic fatty liver (NAFLD) are lower than in their healthy counterparts. Omega-3 supplementation can be effective in controlling glycemic indices in T2DM, and in improving lipid profiles in T2DM and NAFLD as well. The aim of this study was to evaluate the effects of omega-3 fatty acid supplementation on glycemic control and lipid profile in patients with T2DM and NAFLD. METHODS: In this randomized double-blind placebo-controlled clinical trial, 60 patients with T2DM and NAFLD were enrolled. The participants were randomly divided into two groups. The omega-3 group (OG) received capsules containing omega-3 fatty acids (2g/d), and the placebo group (PG) received placebo capsules (2g/d) during a12 week period. Dietary intake was assessed with 24-hour dietary recalls. Fasting blood samples and anthropometric measurements were collected at the baseline and after 12 weeks. Serum levels of glycemic indices (fasting blood glucose (FBG) levels, glycosylated hemoglobin (HbA1c)) and lipid profile (levels of triglyceride (TG), total cholesterol (TC), low density lipoprotein cholesterol (LDL-c) and high density lipoprotein cholesterol (HDL-c)) were measured. RESULTS: Fifty-six patients completed the study. Paired t-test revealed no significant differences in the baseline measurements between the two groups. At the end of the study compared with the PG, the OG had a significant reduction in serum TG levels. However, there was no significant effect of omega-3 supplementation on the other parameters: the mean FBG or HbA1c concentration, neither on TC, LDL-c and HDL-c levels. CONCLUSION: Two grams per day of omega-3 supplementation after 12 weeks led to a significant reduction in serum TG levels in patients with T2DM and NAFLD. However, no significant effects were observed on FBG, HbA1c, TC, LDL-c, and HDL-c levels.

Relationship Between Renal Function Test Serum and Lipid Profile in Patients with Diabetes Mellitus

The prevalence of diabetes mellitus in the world is increasing. Hyperglycemia in diabetes mellitus can increase the risk of complications in various organs, one of which is chronic renal failure. Diabetic patients with chronic renal failure have an increased risk of cardiovascular disease 10 times higher. Cardiovascular disease is closely related to lipid profile results, one of which is triglycerides as an index of cardiovascular disease risk. In chronic renal failure a decline in kidney function is chronic resulting in glomerular filtration rate falling by more than 50% and will increase the levels of BUN and creatinine in the blood. Levels of BUN and creatinine serum is used as a parameter of kidney function tests. This study aims to determine the relationship between serum BUN and creatinine levels against serum triglyceride levels in patients with diabetes mellitus. This was an observational analytic study with cross sectional design. A sample of 50 was taken selectively at Aisyiyah Siti Fatimah Tulangan Hospital in January 2016 - March 2018. The average BUN was 28.59 mg/dL, the creatinine averaged 2.02 mg/dL and the triglyceride averaged 287.96 mg/dL. Multiple linear regression test results showed significant relationship between BUN with Triglyceride serum (b = -3.73; p = 0.048) and creatinine with Triglyceride serum (b = 83.18; p = 0.002). Based on the results, it is found that there is a significant relationship between BUN and creatinine serum against serum triglyceride in diabetes mellitus patients.

Orlistat Therapy for Children With Type 1 Hyperlipoproteinemia: A Randomized Clinical Trial

Patients with type 1 hyperlipoproteinemia (T1HLP), a rare genetic disorder, have extreme chylomicronemia and recurrent episodes of acute pancreatitis. Currently, the only therapeutic option is to consume an extremely low-fat diet because the triglyceride-lowering medications are not efficacious. To determine the efficacy of orlistat, a gastric and pancreatic lipase inhibitor, in reducing serum triglyceride levels in patients with T1HLP. We conducted a randomized, open-label, clinical trial with a four-period, two-sequence ("orlistat" and "off orlistat" for 3 months), crossover study design. Two unrelated young Asian Indian males (11 and 9 years old) with T1HLP due to homozygous large GPIHBP1 deletions were enrolled at the UT Southwestern Medical Center. The patients were randomized to receive 3 months of orlistat or no therapy (off), then crossed over to the other arm, and this sequence was then repeated. Fasting serum triglyceride levels, fat-soluble vitamins, and gastrointestinal side effects were assessed. Compared with the two off periods, orlistat therapy reduced serum triglycerides by 53.3% and 53.0% in patient 1 and 45.8% and 62.2% in patient 2. There was no deficiency of fat-soluble vitamin levels, and their growth continued. There were no serious adverse effects of orlistat; patient 1 had a mild increase in passage of gas and bloating, and patient 2 had constipation with mild stool leakage. Orlistat is safe and highly efficacious in lowering serum triglycerides in children with T1HLP and should be the first-line therapy in conjunction with an extremely low-fat diet.

Effectiveness of n-3 fatty acids in the treatment of hypertriglyceridemia in HIV/AIDS patients: a meta-analysis.

Hypertriglyceridemia is common in antiretroviral therapy-treated patients and Omega 3 fatty acids are being used as a intervention in reducing serum triglycerides (TG) in these patients. The objective of this study is to evaluate the effectiveness of the use of Omega 3 in the treatment of hypertriglyceridemia in HIV/AIDS patients on antiretroviral therapy. This study is a systematic review with meta-analysis of randomized clinical trials. Electronic databases - PubMed, Cochrane and Lilacs were researched. Fifty one articles were encountered. Nine were added to the meta-analysis. The reduction of triglycerides level was -77.55 mg (IC of -121.85 to -33.25) in Omega 3 groups. The analysis considering trials with more than 1000 mg of EPA/DHA included seven studies and the heterogeneity dropped to 0%.The reduction of combined averages was -101.56mg (IC of -145.76 to -57.37). The analysis considering trials with patients that had more than 200 mg/dL of initial triglycerides included also seven trials and the heterogeneity dropped to 0%. The reduction of combined averages was -114.15 mg (IC of -162.34 to -65.97). EPA/DHA supplementation reduces serum triglycerides levels in patients with HIV/AIDS-associated hypertriglyceridemia in stable use of antiretroviral therapy.

Effect of Amygdalus scoparia kernel oil consumption on lipid profile of the patients with dyslipidemia: a randomized, open-label controlled clinical trial.

BackgroundAmygdalus scoparia kernel (ASK) oil is traditionally used for Hyperlipidemia. Compared to olive oil, it has higher proportion of unsaturated to saturated fatty acid besides exhibiting higher index of oxidative stability. The lipid-lowering effects of ASK oil however, has not been investigated yet. This study is the first one to evaluate such effects in patients with dyslipidemia.ResultsSerum triglyceride levels significantly decreased in the intervention compared to control group (24.80 ± 51.70 vs 3.13 ± 44.80, p-value = 0.03). Serum total cholesterol, LDL and HDL cholesterol levels did not change significantly (p = 0.28 and p = 0.68 and p = 0.10 respectively).Materials and MethodsIn a double arm, open-label, randomized controlled trial,101 hyperlipidemic patients were recruited. The designation of hyperlipidemia was upon meeting either of the three criteria: having serum low-density lipoprotein (LDL) cholesterol level 130–190 (mg/dl), serum triglyceride level 150–400 (mg/dl), and serum high-density lipoprotein (HDL) cholesterol level less than 50 (mg/dl) for women and 40 (mg/dl) for men. Patients who have ever been prescribed with an antihyperlipidemic medication were excluded. They were randomly assigned to intervention group, receiving the ASK oil, for 60 days and control group. Serum lipid measurements were repeated at the end of the intervention period.ConclusionsASK oil supplementation may have a positive effect in reducing serum triglyceride level in patients with dyslipidemia without significant effect on serum cholesterol levels.

Impact of Serum Triglycerides on Clinical Outcomes in Acute Pancreatitis: Findings from a Regional Integrated Healthcare System

Introduction: Hypertriglyceridemia is an established risk factor for acute pancreatitis. This study seeks to evaluate the effect of serum triglycerides on the development of persistent or multiple organ failure in patients with acute pancreatitis. Methods: A retrospective cohort study was conducted using data from an integrated healthcare system. Patients hospitalized for acute pancreatitis between January 1, 2006 and December 31, 2013 were included in the study. Triglyceride levels measured prior to and within 72 hours of admission were compared. In addition, the impact of serum triglycerides on the development of persistent or multiple organ failure during hospitalization for acute pancreatitis was assessed using Poisson regression models adjusting for age and sex. Results: Among 2,519 patients, 267 patients (10.6%) developed organ failure, of which 75 patients (28.1%) developed multiple system organ failure and 82 patients (30.7%) developed persistent organ failure. Serum triglyceride levels in patients who developed organ failure were initially much higher than in patients who did not develop organ failure, but by 72 hours into the admission, approached levels of the patients who did not develop organ failure. Approximately 7% of patients had very high serum triglyceride levels (>500 mg/dL), which correlated with similarly high triglycerides levels prior to admission. Conclusion: Increased TG levels were associated with the development of multiple or persistent organ failure in this study of patients hospitalized with acute pancreatitis. Patients with high triglyceride levels at the time of admission for acute pancreatitis were likely to have high triglyceride levels prior to admission.

Association of Hypertriglycerideamia with Ischaemic Stroke

Stroke is one of the foremost causes of morbidity, mortality and is a socioeconomic challenge. This is particularly true for developing countries like Bangladesh, where health support system including the rehabilitation system is not within the reach of common people. Hypertriglycerademia has an effective influence in the pathogenesis of Ischaemic Stroke (IS). So, the focus of this study was to evaluate and assess the association of serum triglyceride level in patients of IS. This case control study was carried out in the Department of Neurology in collaboration with Department of Biochemistry, BSMMU, Dhaka from July 2011 to June 2013. In this study, 60 diagnosed cases of ischaemic stroke patients and 60 age and sex matched healthy controls were enrolled. Risk factors of Ischemic Stroke (IS) patients were assessed ( adjusted Odds Ratio) in comparison with healthy adults. In this study, being married [OR. 1.95, 95% CI (0.40-9.42), p=0.409] , smoker [OR.1.65, 95% CI (0.57 - 4.82),p= 0.357], DM [OR. 1.48, 95% CI (0.36-6.06), p=0.582 ], IHD [OR. 1.51, 95% CI (0.29 – 7.89), p=0.624] , HTN [OR. 3.66, 95% CI (1.11–12.12), p=0.033] , overweight [OR.2.31, 95% CI (0.77 – 6.91), 0.135] and obesity [OR. 16.19, 95% CI (1.31–200.6), p=0.030] , increased level of serum TC [OR.8.24, 95% CI (2.07 – 32.83), p=0.003], TG [OR. 9.40, 95% CI (1.17 -75.86), p=0.035], LDL [OR. 0.45, 95% CI (0.10–2.05), p=0.308],and decreased level of HDL [OR. 3.37, 95% CI (1.03 - 12.25), p=0.045] were found as risk factors in developing IS. Independent t-test was done to find out the statistically significant differences of continuous variables like serum lipid profile between case and control group. The mean (SD) value of TG which is focus of this study, was found 237.67 (61.74) in case group, and 169.97 (26.95) in control group which was highly statistically significant (p &lt; 0.0001). All of the significant variables were entered into stepwise logistic regression analysis model. From the logistic regression model, it can be finally concluded that hypertension, obesity, increased level of TC, increased level of TG and decreased level of HDL were statistically significant risk factors for development of IS.&#x0D; Bangladesh Journal of Neuroscience 2016; Vol. 32 (1): 34-38

Obesity, hormonal and metabolic abnormalities in adolescent girls with polycystic ovary syndrome

Polycystic ovary syndrome is associated with metabolic abnormalities, such as dyslipidemia, obesity, glucose intolerance, which are also components of the metabolic syndrome. Central obesity and insulin resistance appear to play an important role in the pathogenesis of polycystic ovary syndrome, perhaps via subsequent steroidogenic dysregulation. The aim of the authors was to assess metabolic and hormonal abnormalities in adolescent girls with polycystic ovary syndrome. The study included 52 adolescents diagnosed with polycystic ovary syndrome based on the Rotterdam criteria. Anthropometric, hormonal and metabolic parameters were evaluated among all subjects. 20 healthy, age-matched, non-obese, regularly menstruating girls were used as controls. Of the 52 patients, 15 patients were born with low-birth-weight and 37 patients were born with normal birth weight. Oral glucose tolerance test was performed in all patients and controls. The age of patients was 16.8±3.1 years, and the age of controls was 16.95±2.1 years. Among patients with polycystic ovary syndrome the prevalence of overweight and obesity was 35% (n = 18), while impaired fasting glucose occurred in one patient, impaired glucose tolerance in 8 patients, insulin resistance in 25 patients and metabolic syndrome in 12 patients. Serum triglyceride levels in patients and controls were 1.4±0.8 and 0.9±0.3 mmol/l, respectively (p<0.05), while fasting blood glucose, total cholesterol, HDL and LDL cholesterol were not different in the two groups. Metabolic abnormalities and obesity were more severe and more frequent in patients with low-birth-weight compared to those born with normal weight. There was a negative correlation between birth weight and body mass index SDS values and a positive correlation between fasting insulin levels and body mass index SDS (r = 0.37) in patients born with low-birth-weight. Abnormal glucose metabolism is frequently present in adolescents with polycystic ovary syndrome. It is possible that early diagnosis of polycystic ovary syndrome in adolescence may prevent some of the long-term complications associated with this syndrome.

1054 FACTORS ASSOCIATED WITH ESTIMATED DAILY SALT INTAKE IN PATIENTS WITH HYPERTENSION AND CHRONIC KIDNEY DISEASE

Objectives: Salt restriction is one of the important life-style modifications for prevention and/or management of hypertension. Although guidelines for management of hypertension recommend that daily salt intake is < 6 g/day, it is still higher in Japan than in Western countries. We examined current status of estimated salt intake in Japanese patients with hypertension and/or chronic kidney disease. Methods: Consecutive outpatients (n = 985) who had been measured estimated salt intake were enrolled. The estimated salt intake was calculated using the formula of the Japanese Society of Hypertension Guideline for the Management of Hypertension (JSH2009). We examined percentage of attaining target estimated salt intake (<6 g/day) and its correlates. Results: Baseline values of age, female gender, office blood pressure (BP), body mass index (BMI) and estimated salt intake were 59.5 ± 17.9 years, 53.3 %, 127 ± 19/74 ± 12 mmHg, 25.1 ± 4.3 kg/m2 and 8.3 ± 2.3 g/day, respectively. The attaining target level of estimated salt intake was 15.1%. The office diastolic BP, BMI, hemoglobin A1c and serum triglyceride levels in patients who attained target estimated salt intake were significantly lower than in patients who did not attain it. Age and gender adjusted logistic analysis indicated that obesity (odds ratio = 0.61, 95% CI = 0.43 – 0.88, p < 0.01) and diabetes mellitus (odds ratio = 0.62, 95% CI = 0.38 – 0.99, p < 0.05) were negatively associated with attaining target estimated salt intake. Conclusions: The attaining target level of estimated salt intake is still low in Japanese patients, especially in diabetic and obese patients.

Effects of total and green vegetable intakes on glycated hemoglobin A1c and triglycerides in elderly patients with type 2 diabetes mellitus: The Japanese Elderly Intervention Trial

Many reports have shown that vegetable intake is effective in inhibiting the onset and progression of diabetes mellitus, although the amount of vegetable intake required to be effective remains as unclear. The present study therefore aimed to clarify the relationship between the amount of vegetable intake and glycated hemoglobin A1c (HbA1c) and other metabolic parameters using male Japanese type 2 diabetic patients aged 65 years or older as subjects. Participants were 417 male type 2 diabetic patients aged 65 years or older enrolled in the Japanese Elderly Diabetes Intervention Trial. Dietary intakes were measured by using the Food Frequency Questionnaires method. The patients were divided into five groups by their daily total vegetable intake (A1: ~100 g, A2: 100~150 g, A3: 150~200 g, A4: 200~300 g, A5: 300 g~), and compared HbA1c and other metabolic parameters. Furthermore, the relationship between daily green vegetable intake and HbA1c and other metabolic parameters were examined among five groups divided by quintile methods. There were significant decreases in HbA1c, triglycerides and waist circumference with an increase of total vegetable intake. A significant decrease of HbA1c levels was observed in patients with a daily total vegetable intake of 150 g or more. Furthermore, there was a significant decrease of serum triglyceride levels in patients with a total vegetable intake of 200 g or more. HbA1c levels showed a decreasing tendency with the increase of green vegetable intake, and HbA1c levels in the Q1 group (green vegetable intake: less than 40 g) was significantly higher than those in the other four groups (anovaP = 0.025). In addition, there were significant decreases of body mass index, triglyceride levels and waist circumference with the increase of green vegetable intake. Triglyceride levels decreased significantly from the Q3 group (green vegetable intake: 70 g or more) to the Q5 group (green vegetable intake: 130 g or more; anovaP = 0.016). In the group with a lower intake of total vegetables and green vegetables, the protein energy ratio decreased significantly. As a result, the fat energy ratio and energy intake tended to increase with the decrease of total and green vegetable intakes. Furthermore, intake of grains, sweets and alcoholic beverages increased with the decrease of total vegetable intake. In contrast, intake of nuts, potatoes, sugar, legumes, fruit, seaweed and fish increased with the increase of total vegetable intake Daily total vegetable intake of 200 g or more, and green vegetable intake of 70 g or more correlated with improved control of HbA1c and triglyceride levels in elderly type 2 diabetes patients through achieving a well-balanced diet.